Introduction
Methods
Overview of the Study
Patients
HCT Data
Results
Patient Characteristics and Diagnosis of DADA2
Patient ID | Sex/Ethnicity | Age at disease onset (y) | Age at genetic diagnosis (y) | DADA2 clinical manifestations | CD4, CD8, CD19, CD56 | IgG | IgA | IgM | Previous treatment | Reference |
---|---|---|---|---|---|---|---|---|---|---|
P1* | M, Caucasian | 0.5 | 5 | RCA, pancytopenia, splenomegaly, recurrent infections, LAP | 653, 93, 11, 0.5 | 997 | 2.4 | 7 | Prednisone, sirolimus, tacrolimus, IVIG | |
P2 | F, Tunisian | 7 | 28 | PRCA, stroke, EBV viremia, livedo, splenomegaly, aphthous ulcers | 370,84, 60, 48 | 1700 | 60 | 310 | Prednisone, everolimus, hydroxychloroquine, IVIG | [9] |
P3 | F, Turkish | 1 | 3 | PRCA | 1460, 690, NA, 255 | 1200 | 77 | 77 | Prednisone | [24] |
P4 | M, Turkish | 11 | 22 | PRCA, HSM, MDS-RCMD, recurrent infections, FTT | NA | 682 | 50 | 61 | Prednisone | [24] |
P5 | M, Caucasian | 0.3 | 9 | PRCA, splenomegaly, IBD, recurrent fevers, aphthous ulcers | 607, 781, 685, 90 | 290 | 119 | 9 | Prednisone, anakinra | [21] |
P6 | M, Caucasian | 0 | 15 | Neutropenia, HSM, LAP, livedo, strabismus, PAN, neuropathy | 1239, 714, 116, 339 | 1021 | 77 | 149 | Prednisone, etanercept, adalimumab, CsA, GCSF | |
P7 | M, Caucasian | 2 | 22 | Anemia, lymphopenia, HSM, livedo, ICH, optic nerve atrophy, PAN | 50, 50, 1, 10 | 465 | 47 | 17 | Prednisone, azathioprine, infliximab, FFP, IVIG | [21] |
P8 | M, Caucasian | 0 | 2 | PRCA, LAP, HSM, recurrent infections, liver fibrosis | 1763, 1037, 415, 104 | 426 | < 8 | < 6 | Prednisone, IVIG | [21] |
P9 | F, Caucasian | 2.5 | 4 | RCA, pancytopenia, livedo, epilepsy, T-LGL, HSM, aphthous ulcer | 386, 257, NA, NA | 1000 | NA | 74 | Prednisone | |
P10 | F, Caucasian | 7 | 11 | RCA, pancytopenia, AIHA, splenomegaly, ICH, livedo, arthritis | 528, 211, 26, 30 | 816 | < 26 | 25 | Prednisone, MTX, infliximab, IVIG | [21] |
P11 | F, Caucasian | 1 | 26 | Pancytopenia, HSM, recurrent infections, PAN, bronchiectasis | 183, 108, 0, 2 | 700 | 42 | 33 | Prednisone, azathioprine, daratumumab, etanercept, CsA, rituximab, IVIG, GCSF | |
P12* | M, Caucasian | 0.4 | 4 | Anemia, neutropenia, HSM, LAP, IBD, SAH, TIA, recurrent infections | 599, 278, 228, 147 | 436 | 17 | 54 | Prednisone, azathioprine, sirolimus, etanercept, IVIG | [21] |
P13 | M, Caucasian | 4 | 4 | RCA, pancytopenia, FTT, fevers, arthralgia | 1926, 2005, 1, 74 | 1000 | 16 | 10 | Prednisone, etanercept, eltrombopag, infliximab, rituximab, IVIG | |
P14 | F, Caucasian | 12 | 13 | Neutropenia, lymphopenia, recurrent infections, aphthous ulcers | 190, 172, 26, 35 | 730 | 81 | 27 | Etanercept | |
P15 | M, Caucasian | 3 | 4 | PRCA, HSM, alopecia, recurrent fevers, strabismus, aphthous ulcers | 814, 459, 104, 60 | 605 | 40 | < 6 | Prednisone, MMF, CsA, sirolimus, IVIG, GCSF | |
P16 | M, Caucasian | 0.1 | 13 | SAA, HSM, livedo, IDDM, GHD, hypothyroidism | 1610, 940, 1250, 1040 | 360 | 60 | 30 | None | |
P17 | F, Caucasian | 0.3 | 6 | PRCA, splenomegaly, recurrent infections, livedo, arthritis, T-LGL | NA | 760 | 116 | 52 | Prednisone, etanercept | |
P18 | M, Caucasian | 0.2 | 6 | RCA, neutropenia, HSM, LAP, portal HTN, hepatoportal sclerosis/fibrosis, recurrent infections | 154, 280, 225, 224 | 883 | 88 | 60 | Prednisone, etanercept, GCSF | |
P19 | M, Hispanic | 14 | 15 | Neutropenia, HSM, NRH | 185, 310, 38, 26 | 1247 | 20 | 6 | Adalimumab, IVIG, GCSF | |
P20 | F, Caucasian | 16 | 25 | Neutropenia, HSM, recurrent infections, lymphoproliferation | 1670, 1721, 106, 101 | NA | NA | NA | Prednisone, ATG, GCSF | [21] |
P21 | F, Black | 12 | 12 | Anemia, neutropenia, LAP, HSM, recurrent infections, EBV, bronchiectasis, DLBCL | 170, 176, 127, 83 | 580 | 49 | 31 | Prednisone, rituximab, DLBCL-type chemotherapy | [25] |
P22 | F, Hispanic | 7 | 21 | Neutropenia, recurrent infections | 361, 262, 0, 32 | NA | NA | NA | Prednisone, IVIG, GCSF | |
P23 | F, Caucasian | 3 | 5 | ALPS-like, recurrent infections, neutropenia, splenomegaly, livedo | 976, 738, 596, 263 | 2950 | 348 | 25 | Prednisone, sirolimus, MMF, CsA, GCSF | [23] |
P24 | F, Algerian | 6 | NA | Neutropenia, AIHA, HSM, recurrent infections, livedo | 1208, 1779, 34, 134 | 225 | 2 | 37 | Prednisone, etanercept, sirolimus, rituximab, IVIG | |
P25 | F, Turkish | 0.3 | 2 | PRCA, HSM, recurrent infections, livedo | 960, 980, 756, 142 | 1000 | 109 | 36 | Prednisone | [24] |
P26 | F, Caucasian | 2 | 22 | Neutropenia, stroke, T-LGL, recurrent infections, splenomegaly, livedo | 590, 1450, 121, 6 | 487 | 55 | 394 | Prednisone, etanercept, hydroxychloroquine | |
P27 | F, Caucasian | 1 | 9 | Pancytopenia, stroke, ICH, livedo, arthritis, AML, HSM, HTN, CMP | 273, 222, 23, 29 | 354 | 34 | 9 | Prednisone, etanercept, anakinra, azathioprine, IVIG | |
P28 | F, Caucasian | 14 | 15 | RCA, neutropenia | 441, 276, 43, 35 | 499 | 11 | 15 | Prednisone, IVIG | [21] |
P29* | M, Hispanic | 0 | 18 | PRCA, aphthous ulcers, moderate liver siderosis, hepatitis | NA | NA | NA | NA | Prednisone | [21] |
P30* | F, Hispanic | 13 | 14 | RCA, neutropenia, liver fibrosis, recurrent warts, livedo | 588, 416, 176, 25 | 625 | 86 | 10 | Adalimumab, IVIG |
Patient ID | ADA2 allele 1 | ADA2 allele 2 | ADA2 activity pre-HCT | ADA2 activity post-HCT |
---|---|---|---|---|
P1* | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | NA | 22.07a |
P2 | c.(753 + 168_754-229)del | c.(1081 + 139_1082-92)del | 2b | 490b at 1y |
P3 | c.680-681del (p.Y227fs*27) | c.680-681del (p.Y227fs*27) | NA | NA |
P4 | c.1445 A > G (p.Y482C) | c.1445 A > G (p.Y482C) | NA | 44.38a |
P5 | c.144del (p.R49fs) | c.47 + 2 T > C (splice site) | 0.2a | 11.7a |
P6 | c.506G > A (p.R169Q) | c.139G > T (p.G47W) | 0.37a | 1.67 of normal |
P7 | c.506C > T (p.R169Q) | c.2 T > C (p.M1T) | NA | NA |
P8 | c.144delG (p.R49fs) | c.506G > A (p.R169Q) | NA | NA |
P9 | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | 0.0a | NA |
P10 | c.660C > A (p.Y220X) | c.660C > A (p.Y220X) | 2.5b | 403.6b at 2y |
P11 | c.3936delG (p.R131Sfs) | c.3936delG (p.R131Sfs) | 1.2b | NA |
P12* | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | 0.11a | 76.5b |
P13 | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | 0b | 77.8b at 2.5 m |
P14 | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | 0.09a | NA |
P15 | c.1110C > A (p.N370K) | c.1072G > A (p.G358R) | 0.6a | 19.7a at 1y |
P16 | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | NA | 8.3a at 10y |
P17 | c.506G > A (p.R169Q) | c.932 T > G (p.L311R) | 0.3a | NA |
P18 | c.336C > G (p.H112Q) | del exon 7 | 0.4a | 0.4 of normal |
P19 | c.506G > A (p.R169Q) | c.336C > G (p.H112Q) | NA | NA |
P20 | c.140G > T (p.G47V) | c.336C > G (p.H112Q) | NA | NA |
P21 | c.934C > T (p.R312X) | c.709delC (p.Glu237fs) | 0.2a | 35.6a at 2 m |
P22 | c.794C > G (p.S265X) | c.794C > G (p.S265X) | 0.0a | 10.8a at 1y |
P23 | c.1367A > G (p.Y456C) | c.1196. G > A (p.W399X) | NA | 21.4a |
P24 | c.140G > T (p.G47V) | c.140G > T (p.G47V) | NA | NA |
P25 | c. 1072 G > A (p.G358R) | c. 1072 G > A (p.G358R) | 0.52a | NA |
P26 | p.Lys188Pro | g.17188016_17188596del | 0a | 6a |
P27 | c.506G > A (p.R169Q) | c.506G > A (p.R169Q) | 0.8a | 7.0a at 1y |
P28 | c.144dupG (p.R49fs) | c.506G > A (p.R169Q) | NA | NA |
P29* | c.506G > A (p.R169Q) | c.1072G > A (p.G358R) | NA | 22.3a |
P30* | c.506G > A (p.R169Q) | c.1072G > A (p.G358R) | 0.3a | NA |
Hematological Phenotype Pre-HCT
Immunological and Vasculitis Phenotype Pre-HCT
Transplant Characteristics
Patient ID | Year of HCT | Age at HCT (y)/sex | Indication for HCT | HLA match/graft source | Conditioning | GvHD prophylaxis | CD34+ dose (× 106/kg) | aGvHD/grade | cGvHD | Other comp | Last donor chimerism | Last follow-up (m) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
P1* | 2009 | 3/M | RCA, neutropenia | MSD BM | Bu/Cy (MAC) | MMF/CsA | 7.5 | Gut 3 | No | ITP, SOS on D + 60 | 3 y > 95% | 114 |
P2 | 2018 | 28/F | PRCA | MSD BM | Bu/Flu (MAC) | CsA | 4.3 | No | No | None | 2 y 91% (myeloid 100%) | 26 |
P3 | 2016 | 3/F | PRCA | MRD BM (ADA2 carrier) | Bu/Flu/TT (MAC) | MTX/CsA | 5.4 | No | No | None | 2 y 100% | 48 |
P4 | 2016 | 23/M | PRCA | MRD PB (unknown ADA2 status) | Bu/Flu (MAC) | MMF/PTCy | 10.5 | Skin 1 | Skin + mouth, mild | None | 6 m 100% | 41 |
P5 | 2015 | 7/M | PRCA | 10/10 MUD BM | Bu/Cy/ATG (MAC) | MTX/CsA | TNC = 7.5 | No | No | None | 1 y 100% | 60 |
P6 | 2019 | 17/M | Neutropenia | 10/10 MUD PB | Bu/Cy/pentostatin/hATG (RIC) | MMF/Tacro/PTCy | 7.7 | Skin 1 | No | None | 1 y 100% | 20 |
P7 | 2016 | 23/M | Severe lymphopenia | 10/10 MUD BM | Bu/Flu/Alem (MAC) | MTX/CsA | 6.4 | No | No | None | 6 m > 95% | 50 |
P8 | 2016 | 2/M | PRCA, recurrent CMV | 10/10 MUD BM | Flu/Treo/TT/ATG (MAC) | MTX/CsA | 8.3 | Skin 2 | No | None | 6 m 100% | 50 |
P9 | 2016 | 5/F | RCA, neutropenia | 10/10 MUD BM | Flu/Treo/TT/Alem (MAC) | MMF/CsA | 9 | Skin 1 | No | None | 1 y 98% | 48 |
P10 | 2016 | 11/F | Pancytopenia, autoimmunity | 10/10 MUD PB | Flu/Treo/TT/ATG (MAC) | MTX/CsA | 3.2 | Skin 1 | No | Steatosis hepatis | 1 y 100% | 50 |
P11 | 2019 | 28/F | Pancytopenia | 10/10 MUD BM | Flu/Treo/TT/Alem (MAC) | MMF/CsA | 4.8 | No | No | None | 6 m 100% | 12 |
P12* | 2016 | 5/M | Recurrent TIA, immunodeficiency | 10/10 MUD PB (2 boosts for declining MC)** | Flu/Treo/Alem (MAC) | MMF/CsA | 8.1 | Skin 1 | No | None | 3 y > 95% | 54 |
P13 | 2020 | 6/M | PRCA | 10/10 MUD BM | Flu/Treo/Alem (MAC) | MMF/Tacro | 5.7 | No | No | None | 6 m 100% | 6 |
P14 | 2018 | 14/F | Neutropenia, severe lymphopenia | 10/10 MUD PB | Flu/Treo/Alem (MAC) | MMF/CsA | 15 | Skin 1 | No | Mild bronchiectasis | 2 y 100% | 22 |
P15 | 2016 | 4/M | PRCA, neutropenia | 10/10 MUD BM | Flu/Mel/Alem (RIC) | MTX/Tacro | 3.2 | No | No | ITP D + 42 | 1 y 98% | 52 |
P16 | 2003 | 4/M | Refractory SAA | 10/10 MUD BM (1st HCT from affected MSD) | Flu/TBI/Alem (RIC) | MTX/CsA | 1.4 | No | No | None | 3 y 100% | 200 |
P17 | 2019 | 6/F | Immune dysregulation | 10/10 MUD BM | Flu/Treo/TT/Alem (MAC) | CsA | 10.8 | Skin 1 | Skin, moderate | None | 3 m 96% | 11 |
P18.1 | 2018 | 7/M | RCA, neutropenia | 10/10 MUD PB | Bu/Cy/pentostatin/hATG (RIC) | MMF/Tacro/PTCy | 9 | No | No | Secondary GF | ||
P18.2 | 2019 | 10/10 MUD PB | Flu/Cy/Alem (NMA) | CsA/PTCy | 3.7 | No | No | Unstable graft | ||||
P18.3 | 2019 | 10/10 MUD PB CD34 selected + 2 week post-HCT DLI | Flu/rATG (NMA) | None | 7.4 | Skin, liver, gut 2 | No | NRH, siderosis | 8 m 100% | 24 | ||
P19.1 | 2017 | 19/M | Neutropenia | 10/10 MUD BM | Bu/Cy/pentostatin (RIC) | MMF/Siro/PTCy | 4.5 | No | No | SOS on D + 21, secondary GF | ||
P19.2 | 2018 | 10/10 MUD PB | Flu/Alem (NMA) | CsA | 8.5 | No | No | Stable NRH | 1 y 100% | 36 | ||
P20 | 2014 | 23/F | Neutropenia | 10/10 MUD BM | Flu/Mel/Alem (RIC) | Prednisone/CsA | TNC = 2.1 | No | No | None | 2 y 98% | 76 |
P21 | 2018 | 13/F | Diffuse large B-cell lymphoma | Haplo brother PB | Flu/Mel/TT/ATG/rituximab (RIC) | alpha–beta TCD | 7 | No | No | None | 1 y 100% | 30 |
P22 | 2013 | 20/F | Neutropenia | Haplo sister BM (ADA2 carrier) | Flu/Bu/Cy/TBI200 (MAC) | Tacro/MMF/PTCy | 0.5 | No | No | None | 3 y 100% | 78 |
P23 | 2015 | 5/F | Neutropenia | 9/10 MMUD BM | Bu/Flu/TT/ATG/ rituximab (MAC) | MTX/CsA | 4.2 | Skin/gut 2 | Gut, mild | None | 1 y 100% | 45 |
P24 | 2018 | 9/F | Neutropenia, AIHA | 9/10 MMUD BM | Bu/Flu/Alem/Rituximab (MAC) | MMF/CsA/PTCy | 5.6 | No | No | SOS on D + 12, ARDS D + 54 | 1 m 100% | 2 (dead) |
P25 | 2020 | 4/F | PRCA | 9/10 MMUD PB | Flu/Treo/TT/ATG (MAC) | MTX/CsA | 4.5 | Skin 2 | No | None | 1 m 100% to 11 m 55% | 12 |
P26 | 2018 | 24/F | Neutropenia | 9/10 MMUD BM | Flu/Treo/TT/ATG/ rituximab (MAC) | MTX/CsA | 3 | No | No | None | 2 y 100% | 51 |
P27 | 2012 | 8/F | Pancytopenia | 9/10 MMUD BM | Flu/Treo/Alem (MAC) | MTX/CsA | 8.6 | No | No | None | 5 y 100% | 98 |
P28.1 | 2016 | 16/F | RCA, neutropenia | 9/10 MMUD BM | Flu/Treo/TT/ATG (MAC) | MTX/CsA | 1.4 | No | No | Primary GF | ||
P28.2 | 9/10 MMUD PB (different donor) | Flu/TT/ATG (RIC) (alpha–beta TCD) | MTX/CsA | 4.9 | No | No | None | 1 m 100% | 42 | |||
P29* | 2007 | 9/M | PRCA | 9/10 MMUD PB (1st HCT from affected MSD) | Flu/TBI450/Alem (RIC) | MTX/CsA | 7.9 | Skin 2 | Skin + liver moderate | AIHA D + 70 bridging liver fibrosis | 3 y 95% | 155 |
P30* | 2017 | 16/F | RCA, neutropenia | 9/10 MMUD BM | Flu/Mel/TT/Alem (RIC) | prednisone/CsA | TNC = 2.5 | No | Skin mild | Hepatitis | 1 y 100% | 36 |